Ipsen and Sutro Biopharma form global licensing deal for an ADC targeting solid tumors

A study published in the journal Nature reports results of the first-in-human phase I clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3. Researchers at Baylor College of Medicine and Texas Children’s Cancer Center led the study, which tested chimeric antigen receptor T cells enhanced with the protein interleukin-15.

One-third of HER2-positive tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d’Hebron Institute of Oncology’s Growth Factors Group, in collaboration with researchers of the Cancer Research Program of Hospital del Mar Research Institute, Barcelona, have developed novel chimeric antigen receptor T-cell therapy that can produce a potent antitumor response against p95HER2-expressing cells.